Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...
AZoNano on MSN4h
Reprogramming Liver Immunity: A Lipid Nanoparticle Approach for Pancreatic Cancer TherapyA novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback